Investment News Show
Money Info Show Airs at
10:00 AM to 11:00 AM EDT
Every Tuesday
LISTEN LIVE
Use this Link To Watch The Show:
www.princetonresearch.com/money-info-live.htm
Be On The Air With Us
Call In Your Questions
888-792-1590
The show featured an interview with Mr. John Mon, COO of Medifocus, Inc. (Stock symbol: MDFZF).
Watch a replay:
Mr. Mon was previously V.P. of business and product development, General Manager, and Director of Celsion. He achieved FDA approvals for IDE/PMA/510K submissions, and has worked with clinicians, engineers, and patent attorneys on thermotherapy and breast-cancer-related devices. Mr. Mon has co-authored several scholarly articles and holds many granted and pending patents in the area of thermotherapy for the treatment of cancer and other diseases.
Get More Investors and Stock Quote information at:
http://medifocusinc.com/index.php/stock-information/
See Medifocus Corporate Fact Sheet March 2013:
http://www.princetonresearch.com/Medifocus-Factsheet-March-2013-Final.pdf
Visit the corporate web site: www.medifocusinc.com
“Improving the outcomes and standards of care in cancerous and benign conditions with minimally invasive focused heat technologies.”
Our treatment is designed with patients’ needs and comfort in mind.
Medifocus, Inc. develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”).
The Company owns two technology platforms with approximately 100 issued and pending US and international patents:
1. The “Endo-thermotherapy Platform”, and
2. The “Adaptive Phased Array Microwave Focusing Platform”.
Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side-effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is a minimally invasive in-office treatment option for the symptoms of enlarged prostate in men. The Prolieve® System is a revenue generating product catering to the $8 billion non-surgical BPH drug market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.
Prolieve®
- Considered a true in-office therapy by Urologists because of its immediate symptom relief, little to no patient discomfort, and no need for sedation
- Current Medifocus management and product development team actually designed and developed the product while at Celsion Corporation.
- Existing nationwide network of nearly 250 physicians using Prolieve has been established
- Unique Rocky Mountain Mobile Services treatment strategy
- Sales strategy focuses on physicians who prescribe the majority of the BPH drugs
MEDICAL STOCK NEWS
Medifocus Inc. Announces DTC Eligibility of Its Common Stock – SEE MORE
Medifocus, Inc. Obtains New US Patent Covering the Use of the Prolieve Thermodilation System for Drug Delivery
Future Use in Treating Prostate and Other Cancers With Drug is Covered by New Patent — SEE MORE
